CODX Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.44 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.98 |
| Beta | -0.83 |
| 11 Month Change | 13.39% |
| 3 Month Change | 32.11% |
| 1 Year Change | 12.50% |
| 33 Year Change | -86.69% |
| 5 Year Change | 32.11% |
| Change since IPO | -75.22% |
Recent News & Updates
Recent updates
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Jun 14
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
May 18A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Apr 14Co-Diagnostics: Hold Thesis Remains Well Intact
Sep 07Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes
Aug 11Co-Diagnostics spikes on shipments of monkeypox test
Jul 11Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Jul 06Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant
Jun 21Co-Diagnostics: Where's Eikon?
Apr 03Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 28Co-Diagnostics: Swinging For The Fences
Jan 24Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?
Dec 28Why Co-Diagnostics Is A Solid Covid-19 Play
Aug 19Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Aug 14Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test
Jun 18Co-Diagnostics: No One-Hit Wonder
Jun 04Shareholder Returns
| CODX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 23.1% | 2.4% | 3.1% |
| 1Y | 12.5% | 9.8% | 25.4% |
Return vs Industry: CODX exceeded the US Medical Equipment industry which returned 11.2% over the past year.
Return vs Market: CODX underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| CODX volatility | |
|---|---|
| CODX Average Weekly Movement | 18.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CODX's share price has been volatile over the past 3 months.
Volatility Over Time: CODX's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| CODX fundamental statistics | |
|---|---|
| Market cap | US$54.89m |
| Earnings (TTM) | -US$37.57m |
| Revenue (TTM) | US$9.14m |
5.0x
P/S Ratio-1.2x
P/E RatioIs CODX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CODX income statement (TTM) | |
|---|---|
| Revenue | US$9.14m |
| Cost of Revenue | US$3.67m |
| Gross Profit | US$5.47m |
| Other Expenses | US$43.04m |
| Earnings | -US$37.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 59.83% |
| Net Profit Margin | -411.19% |
| Debt/Equity Ratio | 0% |
How did CODX perform over the long term?
See historical performance and comparison